Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2001

View Archived Issues

Licensing opportunity from NIH: biologically active FLAG epitope-tagged TGF-beta protein

Novel inhibitors of retrovirus replication available for licensing from NIH

Revised safety information for Sporanox labeling in Canada

Mechanism of action of HIV-inactivating protein cyanovirin N explored

Oritavancin rapidly kills multidrug-resistant S. pneumoniae in vitro

Safety and efficacy of dopamine agonists in treatment of restless legs syndrome

Results from studies on neuropathic pain treatments presented at AAN meeting

Rabbit studies indicate safety, efficacy of KUR-1246 in threatened premature delivery

Neurocrine Biosciences advances NBI-34060 towards phase III trials for insomnia

Successful completion of initial human trial for testosterone patch announced by 3M

Second azelaic acid-based acne product cleared for launch by FDA

UR-3216 emerges as a promising new gpIIb/IIIa antagonist for cardiovascular disorders

Oral therapy for CML developed at Novartis approved by FDA

Activation of PPARgamma associated with apoptosis in gliomas

Proteasome inhibitor PS-519 holds promise as a therapy for psoriasis

FDA approves Almirall Prodesfarma's 5-HT1B/1D agonist for treatment of migraine

Low-dose loratadine has steroid-sparing effect in Crohn's disease patients

Johnson & Johnson acquisition of Alza proceeds on schedule

KS Biomedix moves KSB-302 into phase IIb for RA

Antifungal agent produced by species of Phoma patented by Sankyo

TPO mimetics in development at GSK

Shionogi presents new series of HIV integrase inhibitors

Merger of BioChem Pharma and Shire officially closes

Inhibitors of VSMC proliferation derived from PGE reported by Taisho

Pfizer presents new glycogen phosphorylase inhibitors and potential uses

6-Azauracils from Pfizer useful as thyroid receptor ligands

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...